Latest Behring Stories
CSL Behring Pioneered Donations to WFH Program; Further Underscores Commitment to Providing Global Bleeding Disorders Community with Access to Treatment KING OF PRUSSIA, Pa., Feb.
New Label Supports Individualized Therapy Through Greater Dosing Flexibility From Daily to Once Every Two Weeks (Biweekly); Underscores CSL Behring's Commitment to Improving Patients' Lives
Led by CSL Behring performance, the company focuses on sustainable business practices, strong results to provide patients with lifesaving, life-enhancing therapies around the world. KING OF
Presentations focus on Hizentra flexible dosing regimens and push administration PRAGUE, Oct.
JNC is the Bleeding Disorders Community's Original Golf and Baseball Competition for Kids with Hemophilia and/or von Willebrand disease (VWD) and Their Families PHOENIX, Oct.
KING OF PRUSSIA, Pa., Oct.
CSL Plasma center openings are on the rise, as is the demand for plasma protein therapies for the treatment of rare and serious diseases. KING OF PRUSSIA, Pa., Oct.
Company further increases global manufacturing capabilities with production expansions of albumin in Australia and plasma intermediates in U.S.
The 140,000-square foot expansion has received regulatory approval from the U.S. Food & Drug Administration. KING OF PRUSSIA, Pa., Sept.
CSL Behring Assists The Jeffrey Modell Foundation and National Association of School Nurses to prepare an information blitz to improve early referral and diagnosis. KING OF PRUSSIA, Pa., Aug.
- A political dynamiter.